Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 plus sorafenib in first-line advanced or inoperable hepatocellular carcinoma
2008-006212-38Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2009
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trebananib and sorafenib in hepatocellular carcinoma (HCC), sponsored by Amgen. Primary endpoint: Time-to-progression event rate at 4 months. Started Mar 2009; status: completed.
02
Drugs
trebananibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-006212-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006212-38.